Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 3
2008 2
2011 1
2012 2
2013 1
2019 1
2020 7
2021 16
2022 5
2023 8
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

44 results

Results by year

Filters applied: . Clear all
Page 1
Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance.
Kristensen LE, Danese S, Yndestad A, Wang C, Nagy E, Modesto I, Rivas J, Benda B. Kristensen LE, et al. Among authors: modesto i. Ann Rheum Dis. 2023 Jul;82(7):901-910. doi: 10.1136/ard-2022-223715. Epub 2023 Mar 17. Ann Rheum Dis. 2023. PMID: 36931693 Free PMC article. Clinical Trial.
Tofacitinib for the Treatment of Ulcerative Colitis: An Integrated Summary of up to 7.8 Years of Safety Data from the Global Clinical Programme.
Sandborn WJ, D'Haens GR, Sands BE, Panaccione R, Ng SC, Lawendy N, Kulisek N, Modesto I, Guo X, Mundayat R, Su C, Vranic I, Panés J. Sandborn WJ, et al. Among authors: modesto i. J Crohns Colitis. 2023 Apr 3;17(3):338-351. doi: 10.1093/ecco-jcc/jjac141. J Crohns Colitis. 2023. PMID: 36124702 Free PMC article. Clinical Trial.
Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open-label, long-term extension study with up to 7.0 years of treatment.
Sandborn WJ, Lawendy N, Danese S, Su C, Loftus EV Jr, Hart A, Dotan I, Damião AOMC, Judd DT, Guo X, Modesto I, Wang W, Panés J. Sandborn WJ, et al. Among authors: modesto i. Aliment Pharmacol Ther. 2022 Feb;55(4):464-478. doi: 10.1111/apt.16712. Epub 2021 Dec 1. Aliment Pharmacol Ther. 2022. PMID: 34854095 Free PMC article.
Infliximab and ulcerative colitis.
Cottone M, Mocciaro F, Modesto I. Cottone M, et al. Among authors: modesto i. Expert Opin Biol Ther. 2006 Apr;6(4):401-8. doi: 10.1517/14712598.6.4.401. Expert Opin Biol Ther. 2006. PMID: 16548766 Review.
Mesalazine for the treatment of inflammatory bowel disease.
Criscuoli V, Modesto I, Orlando A, Cottone M. Criscuoli V, et al. Among authors: modesto i. Expert Opin Pharmacother. 2013 Aug;14(12):1669-78. doi: 10.1517/14656566.2013.808622. Epub 2013 Jun 17. Expert Opin Pharmacother. 2013. PMID: 23767798 Review.
Major Adverse Cardiovascular Events by Baseline Cardiovascular Risk in Patients with Ulcerative Colitis Treated with Tofacitinib: Data from the OCTAVE Clinical Programme.
Schreiber S, Rubin DT, Ng SC, Peyrin-Biroulet L, Danese S, Modesto I, Guo X, Su C, Kwok KK, Jo H, Chen Y, Yndestad A, Reinisch W, Dubinsky MC. Schreiber S, et al. Among authors: modesto i. J Crohns Colitis. 2023 Nov 24;17(11):1761-1770. doi: 10.1093/ecco-jcc/jjad104. J Crohns Colitis. 2023. PMID: 37402275 Free PMC article.
Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19.
Izadi Z, Brenner EJ, Mahil SK, Dand N, Yiu ZZN, Yates M, Ungaro RC, Zhang X, Agrawal M, Colombel JF, Gianfrancesco MA, Hyrich KL, Strangfeld A, Carmona L, Mateus EF, Lawson-Tovey S, Klingberg E, Cuomo G, Caprioli M, Cruz-Machado AR, Mazeda Pereira AC, Hasseli R, Pfeil A, Lorenz HM, Hoyer BF, Trupin L, Rush S, Katz P, Schmajuk G, Jacobsohn L, Seet AM, Al Emadi S, Wise L, Gilbert EL, Duarte-García A, Valenzuela-Almada MO, Isnardi CA, Quintana R, Soriano ER, Hsu TY, D'Silva KM, Sparks JA, Patel NJ, Xavier RM, Marques CDL, Kakehasi AM, Flipo RM, Claudepierre P, Cantagrel A, Goupille P, Wallace ZS, Bhana S, Costello W, Grainger R, Hausmann JS, Liew JW, Sirotich E, Sufka P, Robinson PC, Machado PM, Griffiths CEM, Barker JN, Smith CH, Yazdany J, Kappelman MD; Psoriasis Patient Registry for Outcomes, Therapy and Epidemiology of COVID-19 Infection (PsoProtect); the Secure Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease (SECURE-IBD); and the COVID-19 Global Rheumatology Allianc; Psoriasis Patient Registry for Outcomes, Therapy and Epidemiology of COVID-19 Infection (PsoProtect); the Secure Epidemiology of Coronavirus Under Research Exclusion for Inflammat… See abstract for full author list ➔ Izadi Z, et al. JAMA Netw Open. 2021 Oct 1;4(10):e2129639. doi: 10.1001/jamanetworkopen.2021.29639. JAMA Netw Open. 2021. PMID: 34661663 Free PMC article.
Challenges and Opportunities in IBD Clinical Trial Design.
Dubinsky MC, Collins R, Abreu MT; International Organization for the Study of Inflammatory Bowel Diseases (IOIBD). Dubinsky MC, et al. Gastroenterology. 2021 Aug;161(2):400-404. doi: 10.1053/j.gastro.2021.03.065. Epub 2021 Apr 20. Gastroenterology. 2021. PMID: 33864796 Free article. No abstract available.
44 results